Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2
Combination treatment with shikonin and COX-2 inhibitor may be a suitable therapeutic strategy for EGFR-T790M-mutant NSCLC treatment.
Authors
- Cairong Zhu (ORCID: https://orcid.org/0000-0001-6795-582X)
- Xiaoyan Ye
- Xinpeng Xing (ORCID: https://orcid.org/0000-0002-5535-9577)
- H. Li (ORCID: https://orcid.org/0000-0003-2407-8948)
- Shiyu Cao (ORCID: https://orcid.org/0000-0002-8714-2559)
- Yong‐huan Xie
- Xiaoping Wu (ORCID: https://orcid.org/0000-0002-9447-2935)
- Xiangfeng Zeng
- Xing Zhong (ORCID: https://orcid.org/0000-0003-4359-8455)
- Wenxiu Xing
- Hongjiao Liu
- Xinyi Yang (ORCID: https://orcid.org/0009-0000-4943-5492)
Institutions
- Jinan University (CN)
- Guangzhou Women and Children Medical Center (CN)
- First Affiliated Hospital of Jinan University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1186/s40001-024-02187-7
- Citations
- 7
- Primary Topic
- Bioactive Compounds and Antitumor Agents
- Type
- article
- Field-Weighted Citation Impact
- 2.45
Funders
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Project
- Basic and Applied Basic Research Foundation of Guangdong Province